{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T21:02:04Z","timestamp":1754600524655,"version":"3.28.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00108-024-01766-4","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T08:02:15Z","timestamp":1725264135000},"page":"1076-1081","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aktuelle und neue Impfstoffe gegen Pneumokokken","Current and new vaccines against pneumococci"],"prefix":"10.1007","volume":"65","author":[{"given":"Jessica","family":"Rademacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"issue":"4","key":"1766_CR1","first-page":"114","volume":"121","author":"R Singer","year":"2024","unstructured":"Singer\u00a0R, Abu Sin\u00a0M, Tenenbaum\u00a0T, Toepfner\u00a0N, Berner\u00a0R, Buda\u00a0S et\u00a0al (2024) The increase in invasive bacterial infections with respiratory transmission in Germany, 2022\/2023. Dtsch Arzteblatt Int 121(4):114\u2013120","journal-title":"Dtsch Arzteblatt Int"},{"issue":"9","key":"1766_CR2","doi-asserted-by":"publisher","first-page":"e582","DOI":"10.1016\/S2589-7500(23)00108-5","volume":"5","author":"D Shaw","year":"2023","unstructured":"Shaw\u00a0D, Abad\u00a0R, Amin-Chowdhury\u00a0Z, Bautista\u00a0A, Bennett\u00a0D, Broughton\u00a0K et\u00a0al (2023) Trends in invasive bacterial diseases during the first 2\u00a0years of the COVID-19 pandemic: analyses of prospective surveillance data from 30\u00a0countries and territories in the IRIS consortium. Lancet Digit Health 5(9):e582\u201393","journal-title":"Lancet Digit Health"},{"issue":"10","key":"1766_CR3","doi-asserted-by":"publisher","first-page":"e0184877","DOI":"10.1371\/journal.pone.0184877","volume":"12","author":"R Bornheimer","year":"2017","unstructured":"Bornheimer\u00a0R, Shea\u00a0KM, Sato\u00a0R, Weycker\u00a0D, Pelton\u00a0SI (2017) Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease. PLoS ONE 12(10):e184877","journal-title":"PLoS ONE"},{"issue":"1","key":"1766_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S2213-2600(22)00494-5","volume":"11","author":"P Venkatesan","year":"2023","unstructured":"Venkatesan\u00a0P (2023) GOLD COPD report: 2023 update. Lancet Respir Med 11(1):18","journal-title":"Lancet Respir Med"},{"issue":"5","key":"1766_CR5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1469-0691.2010.03296.x","volume":"17","author":"AHW Bruns","year":"2011","unstructured":"Bruns\u00a0AHW, Oosterheert\u00a0JJ, Cucciolillo\u00a0MC, El Moussaoui\u00a0R, Groenwold\u00a0RHH, Prins\u00a0JM et\u00a0al (2011) Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. Clin Microbiol Infect 17(5):763\u2013768","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"1766_CR6","doi-asserted-by":"publisher","first-page":"9696","DOI":"10.1038\/s41598-021-89038-1","volume":"11","author":"J Kim","year":"2021","unstructured":"Kim\u00a0J, Park\u00a0SJ, Choi\u00a0S, Seo\u00a0WW, Lee\u00a0YJ (2021) Hospitalization for acute coronary syndrome increases the long-term risk of pneumonia: a\u00a0population-based cohort study. Sci Rep 11(1):9696","journal-title":"Sci Rep"},{"issue":"1","key":"1766_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1183\/09031936.00049111","volume":"39","author":"A Singanayagam","year":"2012","unstructured":"Singanayagam\u00a0A, Singanayagam\u00a0A, Elder\u00a0DHJ, Chalmers\u00a0JD (2012) Is community-acquired pneumonia an independent risk factor for cardiovascular disease? Eur Respir\u00a0J 39(1):187\u2013196","journal-title":"Eur Respir J"},{"issue":"3","key":"1766_CR8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/resp.13233","volume":"23","author":"MI Restrepo","year":"2018","unstructured":"Restrepo\u00a0MI, Reyes\u00a0LF (2018) Pneumonia as a\u00a0cardiovascular disease. Respirol Carlton Vic 23(3):250\u2013259","journal-title":"Respirol Carlton Vic"},{"issue":"7","key":"1766_CR9","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.3390\/jcm12072577","volume":"12","author":"ED Meregildo-Rodriguez","year":"2023","unstructured":"Meregildo-Rodriguez\u00a0ED, Asmat-Rubio\u00a0MG, Rojas-Benites\u00a0MJ, V\u00e1squez-Tirado\u00a0GA (2023) Acute coronary syndrome, stroke, and mortality after community-acquired pneumonia: systematic review and meta-analysis. J\u00a0Clin Med 12(7):2577","journal-title":"J Clin Med"},{"issue":"3","key":"1766_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nri2494","volume":"9","author":"AJ Pollard","year":"2009","unstructured":"Pollard\u00a0AJ, Perrett\u00a0KP, Beverley\u00a0PC (2009) Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9(3):213\u2013220","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1766_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ijantimicag.2008.01.021","volume":"32","author":"MW Pletz","year":"2008","unstructured":"Pletz\u00a0MW, Maus\u00a0U, Krug\u00a0N, Welte\u00a0T, Lode\u00a0H (2008) Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 32(3):199\u2013206","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"1766_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/vaccines12020179","volume":"12","author":"K Alexandrova Nikolova","year":"2024","unstructured":"Alexandrova Nikolova\u00a0K, Andersson\u00a0M, Slotved\u00a0HC, Koch\u00a0A (2024) Mortality of invasive pneumococcal disease following introduction of the 13-valent pneumococcal conjugate vaccine in greenland. Vaccines 12(2):179","journal-title":"Vaccines"},{"issue":"33","key":"1766_CR13","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1016\/j.vaccine.2022.06.024","volume":"40","author":"L Huang","year":"2022","unstructured":"Huang\u00a0L, Wasserman\u00a0M, Grant\u00a0L, Farkouh\u00a0R, Snow\u00a0V, Arguedas\u00a0A et\u00a0al (2022) Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States. Vaccine 40(33):4700\u20134708","journal-title":"Vaccine"},{"issue":"4","key":"1766_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","volume":"18","author":"SN Ladhani","year":"2018","unstructured":"Ladhani\u00a0SN, Collins\u00a0S, Djennad\u00a0A, Sheppard\u00a0CL, Borrow\u00a0R, Fry\u00a0NK et\u00a0al (2018) Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a\u00a0prospective national observational cohort study. Lancet Infect Dis 18(4):441\u2013451","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1766_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S1473-3099(20)30165-1","volume":"21","author":"N Ouldali","year":"2021","unstructured":"Ouldali\u00a0N, Varon\u00a0E, Levy\u00a0C, Angoulvant\u00a0F, Georges\u00a0S, Ploy\u00a0MC et\u00a0al (2021) Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a\u00a017-year national prospective surveillance study. Lancet Infect Dis 21(1):137\u2013147","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"1766_CR16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/cid\/ciab990","volume":"75","author":"B Essink","year":"2022","unstructured":"Essink\u00a0B, Sabharwal\u00a0C, Cannon\u00a0K, Frenck\u00a0R, Lal\u00a0H, Xu\u00a0X et\u00a0al (2022) Pivotal phase\u00a03 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-Valent pneumococcal conjugate vaccine in adults aged \u2265\u202f18 years. Clin Infect Dis 75(3):390\u2013398","journal-title":"Clin Infect Dis"},{"issue":"38","key":"1766_CR17","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","volume":"39","author":"NP Klein","year":"2021","unstructured":"Klein\u00a0NP, Peyrani\u00a0P, Yacisin\u00a0K, Caldwell\u00a0N, Xu\u00a0X, Scully\u00a0IL et\u00a0al (2021) A\u00a0phase\u00a03, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49\u00a0years of age. Vaccine 39(38):5428\u20135435","journal-title":"Vaccine"},{"issue":"1","key":"1766_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.vaccine.2021.08.049","volume":"40","author":"HL Platt","year":"2022","unstructured":"Platt\u00a0HL, Cardona\u00a0JF, Haranaka\u00a0M, Schwartz\u00a0HI, Narejos\u00a0PS, Dowell\u00a0A et\u00a0al (2022) A\u00a0phase\u00a03\u00a0trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50\u00a0years of age and older (PNEU-AGE). Vaccine 40(1):162\u2013172","journal-title":"Vaccine"},{"issue":"1","key":"1766_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/14760584.2021.1994858","volume":"21","author":"S Mt-Isa","year":"2022","unstructured":"Mt-Isa\u00a0S, Abderhalden\u00a0LA, Musey\u00a0L, Weiss\u00a0T (2022) Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20. Expert Rev Vaccines 21(1):115\u2013123","journal-title":"Expert Rev Vaccines"},{"key":"1766_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.25646\/11719.2","volume":"39","author":"J Schlaberg","year":"2023","unstructured":"Schlaberg\u00a0J, Vygen-Bonnet\u00a0S, Falman\u00a0A et\u00a0al (2023) Aktualisierung der Empfehlungen der STIKO zur Standardimpfung von Personen \u2265\u202f60\u00a0Jahre sowie zur Indikationsimpfung von Risikogruppen gegen Pneumokokken und die dazugeh\u00f6rige wissenschaftliche Begr\u00fcndung. Epidemiol Bull 39:3\u201344. https:\/\/doi.org\/10.25646\/11719.2","journal-title":"Epidemiol Bull"},{"issue":"6","key":"1766_CR21","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1093\/infdis\/jiad538","volume":"229","author":"MK Ellingson","year":"2024","unstructured":"Ellingson\u00a0MK, Weinberger\u00a0DM, van der Linden\u00a0M, Perniciaro\u00a0S (2024) Potential impact of higher-valency pneumococcal conjugate vaccines among adults in different localities in Germany. J\u00a0Infect Dis 229(6):1669\u20131673","journal-title":"J Infect Dis"},{"key":"1766_CR22","unstructured":"Koch-Institut R (2022) Impfquoten bei Erwachsenen in Deutschland \u2013 Aktuelles aus der KV-Impfsurveillance. Robert Koch-Institut. https:\/\/edoc.rki.de\/handle\/176904\/10490. Zugegriffen: 20. Juni 2024"},{"issue":"1\u201302","key":"1766_CR23","first-page":"e1","volume":"149","author":"S Mihm","year":"2024","unstructured":"Mihm\u00a0S, Schelling\u00a0J, W\u00f6lle\u00a0R, Suck\u00a0A, H\u00e4ckl\u00a0D, Weinke\u00a0T et\u00a0al (2024) Pneumococcal vaccination coverage rates (VCRs) among persons with vaccine-relevant underlying conditions and persons aged 60 years and older\u2014an analysis of secondary data from the statutory health insurance (SHI) system. Dtsch Med Wochenschr 149(1\u201302):e1\u201310","journal-title":"Dtsch Med Wochenschr"},{"key":"1766_CR24","doi-asserted-by":"publisher","first-page":"100409","DOI":"10.1016\/j.lanepe.2022.100409","volume":"18","author":"S Perniciaro","year":"2022","unstructured":"Perniciaro\u00a0S, van der Linden\u00a0M (2022) Correction to \u201epneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: a\u00a0retrospective cohort study\u201c. Lancet Reg Health Eur 18:100409","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"1766_CR25","doi-asserted-by":"publisher","first-page":"15948","DOI":"10.1038\/s41598-021-95129-w","volume":"11","author":"GL Ignatova","year":"2021","unstructured":"Ignatova\u00a0GL, Avdeev\u00a0SN, Antonov\u00a0VN (2021) Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a\u00a05-year follow-up cohort study. Sci Rep 11(1):15948\u201315945","journal-title":"Sci Rep"},{"issue":"9","key":"1766_CR26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1086\/656587","volume":"51","author":"IFN Hung","year":"2010","unstructured":"Hung\u00a0IFN, Leung\u00a0AYM, Chu\u00a0DWS, Leung\u00a0D, Cheung\u00a0T, Chan\u00a0CK et\u00a0al (2010) Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a\u00a0prospective cohort study. Clin Infect Dis 51(9):1007\u20131016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1766_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jinf.2012.04.014","volume":"65","author":"YC Chang","year":"2012","unstructured":"Chang\u00a0YC, Chou\u00a0YJ, Liu\u00a0JY, Yeh\u00a0TF, Huang\u00a0N (2012) Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75\u00a0years or older in Taiwan\u2014a representative population-based comparative study. J\u00a0Infect 65(3):231\u2013238","journal-title":"J Infect"},{"issue":"25\u201326","key":"1766_CR28","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1016\/S0264-410X(03)00296-2","volume":"21","author":"J Hedlund","year":"2003","unstructured":"Hedlund\u00a0J, Christenson\u00a0B, Lundbergh\u00a0P, Ortqvist\u00a0A (2003) Effects of a\u00a0large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a\u00a01-year follow-up. Vaccine 21(25\u201326):3906\u20133911","journal-title":"Vaccine"},{"issue":"8","key":"1766_CR29","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.vaccine.2024.02.035","volume":"42","author":"SO Ali","year":"2024","unstructured":"Ali\u00a0SO, Dessart\u00a0C, Parikh\u00a0R (2024) Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: an overview. Vaccine 42(8):2026\u20132035","journal-title":"Vaccine"},{"issue":"33","key":"1766_CR30","doi-asserted-by":"publisher","first-page":"13564","DOI":"10.1073\/pnas.1307228110","volume":"110","author":"F Zhang","year":"2013","unstructured":"Zhang\u00a0F, Lu\u00a0YJ, Malley\u00a0R (2013) Multiple antigen-presenting system (MAPS) to induce comprehensive B\u2011 and T\u2011cell immunity. Proc Natl Acad Sci U S\u00a0A 110(33):13564\u201313569","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"1766_CR31","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1016\/j.vaccine.2024.02.001","volume":"42","author":"D Borys","year":"2024","unstructured":"Borys\u00a0D, Rupp\u00a0R, Smulders\u00a0R, Chichili\u00a0GR, Kovanda\u00a0LL, Santos\u00a0V et\u00a0al (2024) Safety, tolerability and immunogenicity of a\u00a0novel 24-valent pneumococcal vaccine in toddlers: a\u00a0phase\u00a01 randomized controlled trial. Vaccine 42(10):2560\u20132571","journal-title":"Vaccine"},{"issue":"30","key":"1766_CR32","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1016\/j.vaccine.2021.04.067","volume":"39","author":"D McGuinness","year":"2021","unstructured":"McGuinness\u00a0D, Kaufhold\u00a0RM, McHugh\u00a0PM, Winters\u00a0MA, Smith\u00a0WJ, Giovarelli\u00a0C et\u00a0al (2021) Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice. Vaccine 39(30):4231\u20134237","journal-title":"Vaccine"},{"issue":"31","key":"1766_CR33","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1016\/j.vaccine.2022.05.079","volume":"40","author":"GR Chichili","year":"2022","unstructured":"Chichili\u00a0GR, Smulders\u00a0R, Santos\u00a0V, Cywin\u00a0B, Kovanda\u00a0L, Van Sant\u00a0C et\u00a0al (2022) Phase\u00a01\/2\u00a0study of a\u00a0novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64\u00a0years and in older adults aged 65 to 85\u00a0years. Vaccine 40(31):4190\u20134198","journal-title":"Vaccine"},{"issue":"2","key":"1766_CR34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1473-3099(22)00526-6","volume":"23","author":"H Platt","year":"2023","unstructured":"Platt\u00a0H, Omole\u00a0T, Cardona\u00a0J, Fraser\u00a0NJ, Mularski\u00a0RA, Andrews\u00a0C et\u00a0al (2023) Safety, tolerability, and immunogenicity of a\u00a021-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase\u00a01\/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. Lancet Infect Dis 23(2):233\u2013246","journal-title":"Lancet Infect Dis"},{"key":"1766_CR35","unstructured":"Merck\/MSD (2023) FDA grants priority review to Merck\u2019s new biologics license application for V116, an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults. Pressemitteilung vom 19.\u00a0Dezember 2023. https:\/\/www.merck.com\/news\/fda-grants-priority-review-to-mercks-new-biologics-license-application-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-to-protect-adults\/. Zugegriffen: 22. Dez. 2023"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01766-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T18:01:44Z","timestamp":1731002504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01766-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1766"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01766-4","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"19 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Rademacher gibt folgende Interessenkonflikte an: Forschungsunterst\u00fctzung: BMBF (German Ministry of Research and Education), BMG (Bundesministerium f\u00fcr Gesundheit), Infectopharm, Insmed; Vortragst\u00e4tigkeit: AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, GILEAD, GlaxoSmithKline, MedUpdate, MSD, Pfizer, Seqirus, Shionogi, Streamed Up, ThermoFisher Scientific; Beratert\u00e4tigkeit: Advanz Pharma, GILEAD, GlaxoSmithKline, Shionogi, ThermoFischer Scientific, Insmed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}